Shire PLC (NASDAQ:SHPG) Posts Earnings Results

Shire PLC (NASDAQ:SHPG) released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17, MarketWatch Earnings reports. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $3.70 billion during the quarter. During the same quarter last year, the business posted $3.17 EPS. Shire PLC’s revenue was up 7.1% compared to the same quarter last year. Shire PLC updated its FY17 guidance to $14.80-15.20 EPS.

Shares of Shire PLC (SHPG) opened at $140.36 on Friday. The firm has a market cap of $42,151.51, a P/E ratio of 9.65, a P/E/G ratio of 0.78 and a beta of 1.60. Shire PLC has a 1-year low of $137.80 and a 1-year high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.

A number of equities research analysts recently weighed in on the stock. FBR & Co reiterated a “buy” rating and set a $201.00 price objective on shares of Shire PLC in a report on Monday, October 30th. Cowen and Company set a $225.00 price target on shares of Shire PLC and gave the company a “buy” rating in a report on Sunday, October 29th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $222.00 price objective on shares of Shire PLC in a research report on Friday, October 27th. Zacks Investment Research raised shares of Shire PLC from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $160.00 target price on shares of Shire PLC in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Shire PLC currently has an average rating of “Hold” and an average price target of $211.00.

COPYRIGHT VIOLATION NOTICE: “Shire PLC (NASDAQ:SHPG) Posts Earnings Results” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/shire-plc-shpg-posts-earnings-results-beats-estimates-by-0-15-eps.html.

Institutional investors have recently made changes to their positions in the business. Seizert Capital Partners LLC increased its stake in Shire PLC by 13.3% in the third quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock valued at $1,652,000 after purchasing an additional 1,267 shares during the last quarter. Fisher Asset Management LLC grew its position in shares of Shire PLC by 2.9% during the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after acquiring an additional 1,619 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of Shire PLC by 63.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock worth $2,941,000 after acquiring an additional 6,917 shares during the last quarter. Baldwin Investment Management LLC grew its position in shares of Shire PLC by 1.4% during the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 23 shares during the last quarter. Finally, Oak Ridge Investments LLC grew its position in shares of Shire PLC by 3.2% during the second quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock worth $13,389,000 after acquiring an additional 2,528 shares during the last quarter. Institutional investors own 19.24% of the company’s stock.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Earnings History for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply